Gilead terminates phase II trial of GS 9450 in chronic Hepatitis C after adverse events
Gilead Sciences, Inc announced the company is stopping its ongoing phase-II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.

Read more on PharmaBiz